Certara integrates NVIDIA BioNeMo Agent Toolkit into its open AI platform, unifying biosimulation models, regulatory expertise and proprietary datasets to autonomously generate life sciences insights. Specialized AI agents will optimize dosing strategies, simulate clinical trials and assemble regulatory-ready evidence across the drug development continuum.
Certara has partnered with NVIDIA to embed the BioNeMo Agent Toolkit within its open integrated AI platform, combining scientific software, regulatory expertise and proprietary datasets under an AI-driven, agentic framework.
The BioNeMo Agent Toolkit transforms any AI agent into an autonomous life sciences scientist, enabling them to optimize systems pharmacology models for dosing strategies, interrogate clinical datasets, simulate patient and trial scenarios and evaluate ADMET properties.
This integration unifies Certara’s biosimulation models, datasets and scientific teams with frontier AI to accelerate insight generation, maintain scientific rigor and scale computational drug discovery workflows for over 2,600 biopharmaceutical, academic and regulatory clients worldwide.
